3 sources·Health

Pfizer Halts Development of Oral Obesity Treatment Following Liver Injury Reports

Pfizer has stopped developing its once-daily weight-loss pill, danuglipron, after a patient experienced potential liver injury during trials.

The distribution of story sources: left-leaning (blue), center (light gray), and right-leaning (red).
Reliable
The underlying sources consistently report facts with minimal bias, demonstrating high-quality journalism and accuracy.
Balanced
The underlying sources are either a balanced mix of left and right or primarily centrist.
  1. Pfizer will end development of daily weight-loss pill after liver injury

    The company's decision marks a major setback for the pharmaceutical giant as it competes with rivals Eli Lilly and Novo Nordisk in the lucrative weight-loss drug market.

    Pfizer will end development of daily weight-loss pill after liver injury

    Fox BusinessFox Business·5d
    Mostly Reliable
    This source is generally reliable but sometimes includes opinion, propaganda, or minor inaccuracies.
    ·
    Leans Right
    This outlet slightly leans right.
  2. Pfizer Ends Development of Its Obesity Pill

    Obesity treatments have become one of the more promising and lucrative sectors of drug development for pharmaceutical companies.

    Pfizer Ends Development of Its Obesity Pill

    TIME MagazineTIME Magazine·5d
    Reliable
    This source consistently reports facts with minimal bias, demonstrating high-quality journalism and accuracy.
    ·
    Leans Left
    This outlet slightly leans left.
  3. Pfizer ends development of potential pill obesity treatment

    Obesity treatments have become one of the more promising and lucrative sectors of drug development for pharmaceutical companies.

    Pfizer ends development of potential pill obesity treatment

    Associated PressAssociated Press·5d
    Reliable
    This source consistently reports facts with minimal bias, demonstrating high-quality journalism and accuracy.
    ·
    Center
    This outlet is balanced or reflects centrist views.
  1. Fox Business
  2. TIME Magazine
  3. Associated Press
Updated: Apr 14th, 2025, 11:32 AM ET

Summary

A summary of the key points of this story verified across multiple sources.

Pfizer has decided to cease the development of danuglipron, its oral obesity treatment, after a participant in clinical trials faced liver issues. Despite the setback, Pfizer aims to pursue other obesity treatment options and remains committed to developing innovative medications. The weight-loss drug market is highly competitive, with rivals like Eli Lilly and Novo Nordisk offering alternatives that have generated significant sales. The company’s decision reflects the ongoing challenges in bringing effective weight-loss medications to market in light of potential safety concerns.

Perspectives

Compare opinions on this story from liberal (Left), conservative (Right) or center-leaning news organizations.

  • Pfizer is halting the development of danuglipron, an oral obesity treatment, after a participant in a trial experienced potential liver injury, although similar issues have been seen with other drugs in this category.

  • Despite this setback, Pfizer remains committed to exploring other obesity treatments, as the obesity drug market is seen as a lucrative opportunity for pharmaceutical companies.

  • Leading treatments are injectable, and there's a strong demand for oral alternatives that are more user-friendly, especially given that many patients face challenges accessing current treatments due to cost or insurance issues.

FAQs

A list of follow-up questions readers often ask about this story.

No FAQs available for this story.

Pfizer Halts Development of Oral Obesity Treatment Following Liver Injury Reports - Pano News